
Lisa G M Van Baarsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8782812/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines, 2022, 10, 324.	3.2	4
2	Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool. Arthritis Research and Therapy, 2022, 24, 36.	3.5	1
3	Increased Frequency of CD4+ Follicular Helper T and CD8+ Follicular T Cells in Human Lymph Node Biopsies during the Earliest Stages of Rheumatoid Arthritis. Cells, 2022, 11, 1104.	4.1	13
4	Tertiary Lymphoid Structures: Diversity in Their Development, Composition, and Role. Journal of Immunology, 2021, 206, 273-281.	0.8	72
5	Translational Research Studies Unraveling the Origins of Psoriatic Arthritis: Moving Beyond Skin and Joints. Frontiers in Medicine, 2021, 8, 711823.	2.6	3
6	Lymph node stromal cells: subsets and functions in health and disease. Trends in Immunology, 2021, 42, 920-936.	6.8	18
7	Bridging Insights From Lymph Node and Synovium Studies in Early Rheumatoid Arthritis. Frontiers in Medicine, 2021, 8, 820232.	2.6	1
8	Human Lymph Node Stromal Cells Have the Machinery to Regulate Peripheral Tolerance during Health and Rheumatoid Arthritis. International Journal of Molecular Sciences, 2020, 21, 5713.	4.1	5
9	Multi-HLA class II tetramer analyses of citrulline-reactive T cells and early treatment response in rheumatoid arthritis. BMC Immunology, 2020, 21, 27.	2.2	20
10	Lymph Node Stromal Cells Generate Antigen-Specific Regulatory T Cells and Control Autoreactive T and B Cell Responses. Cell Reports, 2020, 30, 4110-4123.e4.	6.4	46
11	Myeloid Dendritic Cells Are Enriched in Lymph Node Tissue of Early Rheumatoid Arthritis Patients but not in At Risk Individuals. Cells, 2019, 8, 756.	4.1	7
12	Molecular Characterization of Human Lymph Node Stromal Cells During the Earliest Phases of Rheumatoid Arthritis. Frontiers in Immunology, 2019, 10, 1863.	4.8	17
13	The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells. Nature Communications, 2019, 10, 498.	12.8	98
14	BOB.1 controls memory B-cell fate in the germinal center reaction. Journal of Autoimmunity, 2019, 101, 131-144.	6.5	11
15	P113/O17â€Human lymph node stromal cells express self-antigens targeted by anti-citrullinated protein antybodies: role for tolerance induction in rheumathoid arthritis. , 2019, , .		0
16	Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology, 2019, 58, 1075-1085.	1.9	77
17	Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering. Scientific Reports, 2018, 8, 1736.	3.3	20
18	Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 35.	3.5	29

LISA G M VAN BAARSEN

#	Article	IF	CITATIONS
19	Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the Atâ€Risk and Earliest Phases of Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 70-76.	5.6	57
20	Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the atâ€risk phase of autoantibody positive rheumatoid arthritis. European Journal of Immunology, 2016, 46, 2812-2821.	2.9	31
21	A3.06â€Distinct expression pattern of peripheral tissue-restricted antigens in human LYMPH node stromal cells during the earliest phases of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A34.2-A35.	0.9	0
22	A1.19â€Altered distribution of innate lymphoid cell populations in human LYMPH node biopsies obtained during the earliest phases of systemic autoimmunity. Annals of the Rheumatic Diseases, 2016, 75, A8.2-A8.	0.9	0
23	Human lymph-node CD8+ T cells display an altered phenotype during systemic autoimmunity. Clinical and Translational Immunology, 2016, 5, e67.	3.8	23
24	Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. Annals of the Rheumatic Diseases, 2016, 75, 430-438.	0.9	68
25	A8.10â€The effect of rituximab treatment on B and T cell subsets in lymphoid tissues of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A85.1-A85.	0.9	2
26	A1.20â€Lymphoid tissue analyses in autoantibody positive individuals at risk for developing rheumatoid arthritis reveals an important role for CD8 ⁺ T cells during the earliest phases of autoimmunity. Annals of the Rheumatic Diseases, 2015, 74, A9.1-A9.	0.9	0
27	A1.8â€CD4 ⁺ T-helper cell subsets in lymph node biopsies and peripheral blood during the earliest phases of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A3.2-A4.	0.9	Ο
28	A7.7â€Synovial tissue profiling in autoantibody positive individuals without arthritis reveals gene signatures associated with subsequent development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A77.1-A77.	0.9	2
29	JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1763-1771.	0.9	46
30	Tertiary Lymphoid Structures in Rheumatoid Arthritis. American Journal of Pathology, 2015, 185, 1935-1943.	3.8	34
31	Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients. PLoS ONE, 2015, 10, e0133669.	2.5	9
32	Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology, 2014, 53, 770-770.	1.9	3
33	Reply. Arthritis and Rheumatology, 2014, 66, 1683-1684.	5.6	0
34	Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis. Arthritis and Rheumatology, 2014, 66, 513-522.	5.6	140
35	Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics Journal, 2014, 14, 93-106.	2.0	65
36	A1.78â€Ectopic lymphoid neogenesis in rheumatoid arthritis: a potential role for NIK expressing endothelial cells as orchestrators of tertiary lymphoid structures. Annals of the Rheumatic Diseases, 2014, 73, A34.2-A35.	0.9	0

#	Article	IF	CITATIONS
37	Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?. Arthritis Research and Therapy, 2014, 16, 426.	3.5	133
38	A8.34â€CD1C + dendritic cells are overrepresented in lymph nodes of early arthritis patients and related to B cell responses. Annals of the Rheumatic Diseases, 2014, 73, A90.1-A90.	0.9	3
39	OP0256â€Changes of Microrna Expression in Lymph Node Stromal Cells of Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2014, 73, 158.2-158.	0.9	0
40	A1.32â€An imbalance between inflammatory and regulatory T-cell subsets in LYMPH node biopsies during the earliest phases of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A13.2-A13.	0.9	0
41	A8.17â€Expression of the autoimmune regulator aire in human lymph node stromal cells. Annals of the Rheumatic Diseases, 2014, 73, A82.3-A83.	0.9	1
42	A1.73â€Relationship between expression of synovial B cell survival factors and clinical response to rituximab treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A32.1-A32.	0.9	0
43	Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1654-1658.	0.9	150
44	The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1420-1424.	0.9	58
45	A3.13â€Investigating T-Cell Subsets in Lymph Node Biopsies of Autoantibody Positive Individuals and Early Arthritis Patients. Annals of the Rheumatic Diseases, 2013, 72, A18.1-A18.	0.9	Ο
46	A9.6â€Identification of New Potential Therapeutic Targets for the Treatment of Rheumatoid Arthritis: ENTPD1 (CD39) and 5NTE1 (CD73). Annals of the Rheumatic Diseases, 2013, 72, A66.2-A66.	0.9	0
47	THU0007â€Analysis of protein acetylation and histone deacetylase expression in the synovial tissue reveals complex relationships between epigenetic regulatory mechanisms and inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 156.1-156.	0.9	0
48	A1.5â€Exploring the Role of the Lymph Node Microenvironment in Health and Disease. Annals of the Rheumatic Diseases, 2013, 72, A2.2-A2.	0.9	0
49	A7.21â€Suppression of HDAC5 Expression by Inflammatory Cytokines is Required to Promote CXCL Chemokine Production in RA FLS. Annals of the Rheumatic Diseases, 2013, 72, A55.2-A55.	0.9	О
50	Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Annals of the Rheumatic Diseases, 2012, 71, 415-423.	0.9	65
51	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.9	354
52	Histone deacetylase inhibitors prevent inflammation-mediated inactivation of the forkhead box class o transcription factor FOXO1 in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A59.1-A59.	0.9	0
53	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 423-427.	0.9	101
54	Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 858-863.	0.9	23

LISA G M VAN BAARSEN

#	Article	IF	CITATIONS
55	Fms-like tyrosine kinase 3 ligand/CD135 in arthritis: a new inflammatory system in RA?. Annals of the Rheumatic Diseases, 2011, 70, A22-A22.	0.9	0
56	Gene expression profiling in autoantibodyâ€positive patients with arthralgia predicts development of arthritis. Arthritis and Rheumatism, 2010, 62, 694-704.	6.7	87
57	Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis and Rheumatism, 2010, 62, 1602-1607.	6.7	86
58	Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis and Rheumatism, 2010, 62, 3607-3614.	6.7	123
59	Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes and Immunity, 2010, 11, 622-629.	4.1	32
60	The Gene Expression Profile in the Synovium as a Predictor of the Clinical Response to Infliximab Treatment in Rheumatoid Arthritis. PLoS ONE, 2010, 5, e11310.	2.5	96
61	Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. Rheumatology, 2010, 49, 156-166.	1.9	33
62	Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Research and Therapy, 2010, 12, R11.	3.5	115
63	Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Research and Therapy, 2010, 12, 219.	3.5	92
64	Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics, 2009, 10, 97-108.	1.3	28
65	Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes and Immunity, 2009, 10, 210-218.	4.1	48
66	Transcription profiling of rheumatic diseases. Arthritis Research and Therapy, 2009, 11, 207.	3.5	36
67	Expression of a pathogen-response program in peripheral blood cells defines a subgroup of Rheumatoid Arthritis patients. Genes and Immunity, 2008, 9, 16-22.	4.1	40
68	Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2008, 67, 563-566.	0.9	98
69	Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients. PLoS ONE, 2008, 3, e1927.	2.5	105
70	Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Annals of the Rheumatic Diseases, 2007, 66, 1008-1014.	0.9	290
71	Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9. Journal of Investigative Dermatology, 2007, 127, 331-341.	0.7	379
72	Gene Expression Profiling in Rheumatology. Methods in Molecular Medicine, 2007, 136, 305-327.	0.8	14

5

#	Article	IF	CITATIONS
73	A subtype of multiple sclerosis defined by an activated immune defense program. Genes and Immunity, 2006, 7, 522-531.	4.1	84
74	A genomic view of subtypes in rheumatoid arthritis: towards personalized medicine. Future Rheumatology, 2006, 1, 311-322.	0.2	0
75	Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: Evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis and Rheumatism, 2005, 52, 430-441.	6.7	132
76	Title is missing!. Arthritis Research, 2005, 7, P67.	2.0	0
77	Allele-Specific Expression of the IL-1α Gene in Human CD4+ T Cell Clones. Journal of Immunology, 2003, 171, 2349-2353.	0.8	15